PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
NeuroAEye LLC · NCT07185971
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 21–80 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 20
- US sites recruiting
- 2
- Study start
- March 16, 2026
- Record last updated
- April 2, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss.
The primary objective is to demonstrate that there is an improvement in the visual field after use of the PAVE therapy over a period of eight weeks with three sessions per week. The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry.
The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better after PAVE therapy when compared to before therapy.
The participants will visit the investigators office at the start of the study to establish a baseline for visual field size and visual field function. The subject will use PAVE in the office or at home three times per week for eight weeks. There will be twenty four therapy sessions in total. At four weeks the subject will visit the office and have perimetry measurements. At eight weeks the subject will visit the office and have perimetry measurements and complete the NEI-VFQ survey. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.
Being studied: PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
Conditions: Homonymous Hemianopsia; Homonymous Quadrantanopia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset
- The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction.
Exclusion Criteria
- Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy.
- Concurrent use of another visual therapy
- Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.)
- Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects
- Insufficient fixation ability
- Use of life supporting external medical device such as infusion pumps, ventricular assist devices, etc.
- Presence of active implantable medical device including but not limited to cardiac pacemakers, defibrillators, nerve stimulators, cochlear implants, etc.
- Subjects with known photosensitive epilepsy.
- Subjects with chronic active infections on the head and face should be excluded from the study
- Patients with known immune disorders for whom an infection could be life threatening should be excluded from the study.
Recruiting US locations
Dr. D. M. Fitzgerald & Associates
Cedar Rapids, IA 52404
Site contact: Paige Primary Study Coordinator · 319-366-3500 · paige.eyecare@gmail.com
Neuro-Vision Associates of North Texas
Prospect, KY 40059
Site contact: MIchael Lynch, BSME · 502-362-1109 · michael.lynch@neuroaeye.com
Study contacts (from the official record)
- Michael Lynch, BSME · 315-730-9842 · michael.lynch@neuroaeye.com
- Paige Clinical Study Coordinator · 319-366-3500 · paige.eyecare@gmail.com
Similar studies in Iowa
All neurology studies in Iowa →- RecruitingHealthy volunteers
An Early Prospective Study of the Traq™ Device for Characterization of Binocular Ocular Function in Normal Subjects and Subjects With Recent Traumatic Brain Injury
Rebiscan, Inc.
- Location
- Waukee, IA
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Iowa City, IA + 35 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- Iowa City, IA + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- West Des Moines, IA + 111 other US sites
- Eligibility basics
- Ages 18+